
  
    
      
        Background_NNP
        In_IN the_DT course_NN of_IN studies_NNS involving_VBG intravenous_JJ
        adenoviral_NN gene_NN transfer_NN ,_, we_PRP observed_VBD a_DT 10_CD fold_VB difference_NN
        in_IN plasma_NN levels_NNS of_IN the_DT encoded_JJ proteins_NNS between_IN two_CD of_IN the_DT
        rat_NN strains_NNS employed_VBN :_: the_DT Wag_NNP /_NN Rij_NNP and_CC the_DT Brown_NNP Norway_NNP ._.
        These_DT differences_NNS were_VBD observed_VBN for_IN several_JJ vector_NN encoded_JJ
        proteins_NNS as_RB soon_RB as_IN 2_CD days_NNS after_IN gene_NN delivery_NN and_CC were_VBD
        maintained_VBN for_IN one_CD month_NN ,_, after_IN which_WDT the_DT levels_NNS declined_VBD
        slowly_RB to_TO background_NN ._. Other_JJ investigators_NNS described_VBD
        differences_NNS of_IN the_DT same_JJ order_NN of_IN magnitude_NN between_IN mouse_NN
        strains_NNS in_IN expression_NN of_IN transgenes_NNS encoding_VBG α_NN 1_CD -_: antitrypsin_NN
        [_NN 1_CD ]_NN ,_, interleukin-_NN 12_CD [_NN 2_CD ]_NN ,_, and_CC human_JJ endostatin_NN [_NN 3_CD ]_NN ._.
        These_DT differences_NNS in_IN transgene_NN expression_NN between_IN inbred_JJ
        species_NNS may_MD have_VB clinical_JJ implications_NNS ,_, as_IN differences_NNS
        between_IN inbred_JJ strains_NNS are_VBP considered_VBN to_TO reflect_VB
        differences_NNS between_IN individuals_NNS of_IN an_DT outbred_JJ species_NNS ._.
        Consequently_RB ,_, the_DT therapeutic_JJ efficiency_NN of_IN a_DT transgene_NN
        could_MD drastically_RB vary_VB from_IN one_CD patient_NN to_TO another_DT ._. So_RB far_RB ,_,
        a_DT satisfactory_JJ explanation_NN for_IN such_JJ strain_NN differences_NNS has_VBZ
        not_RB been_VBN provided_VBN ._. Most_JJS authors_NNS have_VBP attributed_VBN the_DT
        difference_NN of_IN plasma_NN levels_NNS of_IN vector_NN encoded_JJ protein_NN to_TO
        immune_JJ reactions_NNS against_IN the_DT protein_NN or_CC against_IN the_DT vector_NN
        [_NN 4_CD 5_CD ]_NN ._. However_RB ,_, the_DT kinetics_NNS of_IN the_DT vector_NN encoded_JJ
        proteins_NNS in_IN the_DT plasma_NN do_VBP not_RB support_VB regulation_NN by_IN an_DT
        adaptive_JJ immune_JJ reaction_NN ,_, as_IN the_DT strain_NN difference_NN is_VBZ
        manifest_JJ as_IN early_RB as_IN 2_CD days_NNS after_IN administration_NN of_IN the_DT
        vector_NN ._. Innate_NNP humoral_NN immunity_NN ,_, e_SYM ._. g_SYM ._. the_DT presence_NN of_IN
        neutralising_VBG antibodies_NNS against_IN the_DT vector_NN can_MD also_RB be_VB
        excluded_VBN as_IN the_DT cause_NN of_IN the_DT difference_NN because_IN such_JJ
        antibodies_NNS are_VBP not_RB present_JJ in_IN naïve_NN rats_NNS ._. An_DT innate_JJ
        cellular_JJ immune_JJ reaction_NN directed_VBN against_IN the_DT infected_JJ
        liver_NN cells_NNS is_VBZ also_RB an_DT unlikely_JJ explanation_NN because_IN plasma_NN
        transaminase_NN levels_NNS [_NN 6_CD ]_NN -_: a_DT marker_NN of_IN hepatolysis_NNS -_:
        though_IN somewhat_RB elevated_VBD ,_, are_VBP not_RB different_JJ in_IN the_DT two_CD
        strains_NNS ._.
        The_DT main_JJ organ_NN infected_VBN by_IN an_DT adenovirus_JJ following_NN iv_NN
        injection_NN is_VBZ the_DT liver_NN [_NN 7_CD 8_CD ]_NN ._. Others_NNS and_CC we_PRP find_VBP that_IN
        the_DT liver_NN is_VBZ producing_VBG 95_CD -_: 99_CD %_NN of_IN the_DT vector_NN encoded_JJ protein_NN
        after_IN intravenous_JJ delivery_NN of_IN recombinant_JJ adenoviral_NN
        vectors_NNS ._. The_DT global_JJ process_NN from_IN liver_NN cell_NN infection_NN to_TO
        protein_NN production_NN is_VBZ commonly_RB described_VBN as_IN adenoviral_NN
        permissiveness_NNS of_IN the_DT liver_NN ._. In_IN this_DT study_NN we_PRP investigated_VBD
        which_WDT one_CD of_IN these_DT three_CD processes_VBZ (_( transfection_NN ,_,
        transcription_NN ,_, translation_NN )_) is_VBZ pivotal_JJ for_IN the_DT strain_NN
        difference_NN in_IN transgene_NN expression_NN ._.
        Secreted_NNP vector_NN encoded_JJ proteins_NNS are_VBP not_RB suitable_JJ to_TO
        interpret_VB the_DT early_JJ manifestation_NN of_IN transgene_NN expression_NN ,_,
        as_IN plasma_NN levels_NNS are_VBP highly_RB dependent_JJ on_IN the_DT
        pharmacokinetic_JJ properties_NNS of_IN the_DT encoded_JJ proteins_NNS ._.
        Therefore_RB ,_, we_PRP employed_VBN adenoviral_NN encoded_JJ marker_NN genes_NNS ,_, the_DT
        intracellular_NN Luciferase_NNP (_( Luc_NNP )_) and_CC the_DT nuclear_JJ
        β-_NN Galactosidase_NNP (_( LacZ_NNP )_) ._. The_DT luciferase_NN activity_NN of_IN the_DT
        whole_JJ liver_NN is_VBZ a_DT measure_NN of_IN vector_NN encoded_JJ protein_NN
        expression_NN in_IN that_DT organ_NN while_IN the_DT LacZ_NNP staining_VBG of_IN
        hepatocytes_NNS provides_VBZ information_NN on_IN the_DT proportion_NN of_IN liver_NN
        cells_NNS infected_JJ ._. Furthermore_RB ,_, we_PRP determined_VBD the_DT amount_NN of_IN
        Ad_NN 5_CD DNA_NNP and_CC of_IN transgene_NN mRNA_NN in_IN the_DT liver_NN as_IN measures_NNS of_IN
        the_DT adenoviral_NN infection_NN of_IN hepatic_JJ cells_NNS and_CC of_IN transgene_NN
        transcription_NN respectively_RB ._.
      
      
        Results_NNS
        
          Intravenous_NNP injection_NN of_IN Ad_NN 5_CD vectors_NNS in_IN different_JJ
          rat_NN strains_NNS results_NNS in_IN different_JJ levels_NNS of_IN early_JJ
          transgene_NN expression_NN
          Intravenous_NNP administration_NN of_IN a_DT fixed_VBN dose_NN of_IN Ad_NN 5_CD
          vector_NN either_CC expressing_VBG the_DT human_JJ endostatin_NN gene_NN ,_, or_CC
          the_DT gene_NN for_IN mhATF-BPTI_JJ resulted_VBD in_IN clear_JJ 10_CD -_: fold_VB
          difference_NN in_IN the_DT plasma_NN levels_NNS of_IN both_DT proteins_NNS between_IN
          Brown_NNP Norway_NNP and_CC Wag_NNP /_NN Rij_NNP rats_NNS (_( Fig_NNP ._. 1_LS and_CC 2_LS )_) ._. This_DT
          difference_NN was_VBD detected_VBN as_RB soon_RB as_IN 3_CD days_NNS after_IN the_DT
          vector_NN administration_NN and_CC persisted_VBD during_IN the_DT first_JJ 6_CD
          weeks_NNS ,_, subsequently_RB the_DT plasma_NN levels_NNS of_IN both_DT proteins_NNS
          slowly_RB decreased_VBD to_TO undetectable_JJ levels_NNS in_IN 2_CD to_TO 3_CD months_NNS ._.
          To_TO investigate_VB whether_IN the_DT livers_NNS of_IN the_DT 2_CD rat_NN strains_NNS
          differ_VBP in_IN their_PRP$ permissiveness_NNS for_IN Ad_NN 5_CD or_CC if_IN this_DT
          phenomenon_NN could_MD be_VB explained_VBN by_IN differences_NNS in_IN the_DT
          hepatocyte_NN secretion_NN capacity_NN ,_, we_PRP administrated_JJ Ad_NN 5_CD
          vector_NN carrying_VBG the_DT gene_NN for_IN Luciferase_NNP (_( Ad_NN 5_CD Adapt_NNP Luc_NNP )_) ,_,
          a_DT protein_NN that_WDT is_VBZ not_RB secreted_JJ ._.
          Measurements_NNP of_IN Luciferase_NNP transgene_NN activity_NN in_IN
          various_JJ organs_NNS ,_, following_VBG iv_NN administration_NN of_IN the_DT
          vector_NN ,_, confirmed_VBD the_DT observations_NNS from_IN other_JJ research_NN
          groups_NNS [_NN 7_CD 8_CD ]_NN that_IN in_IN rodents_NNS 95_CD -_: 99_CD %_NN of_IN virus_NN infection_NN
          and_CC subsequent_JJ transgene_NN expression_NN occurs_VBZ in_IN the_DT liver_NN
          (_( Table_NNP 1_LS )_) ._.
          Next_JJ ,_, we_PRP determined_VBD luciferase_NN activity_NN in_IN the_DT liver_NN
          of_IN Brown_NNP Norway_NNP and_CC Wag_NNP /_NN Rij_NNP rats_NNS 2_CD days_NNS after_IN intravenous_JJ
          injection_NN of_IN 10_CD 9_CD iu_NN ,_, 3_CD ._. 10_CD 9_CD iu_NN ,_, or_CC 10_CD 10_CD infectious_JJ units_NNS
          (_( iu_NN )_) of_IN Ad_NN 5_CD Adapt_NNP Luc_NNP ._. The_DT results_NNS depicted_VBN in_IN the_DT Fig_NNP ._.
          3_LS seem_VBP to_TO reflect_VB those_DT observed_VBD with_IN ATF-BPTI_NNP and_CC
          endostatin_NN naming_VBG a_DT 10_CD -_: fold_VB difference_NN between_IN Wag_NNP /_NN Rij_NNP
          and_CC Brown_NNP Norway_NNP rats_NNS ._. These_DT experiments_NNS with_IN the_DT
          non-secreted_JJ luciferase_NN vector_NN encoded_JJ protein_NN confirmed_VBD
          that_IN the_DT two_CD rat_NN strains_NNS have_VBP a_DT very_RB different_JJ liver_NN
          response_NN to_TO the_DT recombinant_JJ adenovirus_JJ ._. Since_IN the_DT levels_NNS
          of_IN mhATF-BPTI_JJ and_CC endostatin_NN reached_VBD a_DT plateau_NN about_IN 7_CD
          days_NNS after_IN vector_NN delivery_NN both_DT in_IN the_DT Brown_NNP Norway_NNP and_CC
          in_IN the_DT Wag_NNP /_NN Rij_NNP rats_NNS ,_, we_PRP also_RB determined_VBD the_DT luciferase_NN
          activity_NN in_IN the_DT liver_NN 7_CD days_NNS post_NN intravenous_JJ
          administration_NN of_IN the_DT Ad_NN 5_CD Adapt_NNP Luc_NNP ._. As_IN shown_VBN in_IN figure_NN
          4_CD ,_, roughly_RB the_DT same_JJ values_NNS were_VBD obtained_VBN at_IN the_DT 2_CD time_NN
          points_NNS ,_, which_WDT reflect_VBP the_DT kinetics_NNS of_IN the_DT plasma_NN
          concentrations_NNS of_IN the_DT secreted_JJ proteins_NNS ATF-BPTI_NNP and_CC
          endostatine_NN ._.
        
        
          β-_NN Galactosidase_NNP expression_NN in_IN hepatocytes_NNS from_IN
          Brown_NNP Norway_NNP and_CC Wag_NNP /_NN Rij_NNP rats_NNS
          To_TO explore_VB whether_IN differences_NNS in_IN the_DT number_NN of_IN
          transduced_JJ hepatocytes_NNS could_MD account_VB for_IN the_DT observed_VBN
          differences_NNS in_IN transgene_NN expression_NN levels_NNS ,_, we_PRP injected_VBD
          different_JJ doses_NNS (_( 10_CD 9_CD iu_NN ,_, 3_CD ._. 10_CD 9_CD iu_NN and_CC 10_CD 10_CD iu_NN )_) of_IN Ad_NN 5_CD
          Adapt_NNP LacZ_NNP into_IN the_DT tail_NN vein_NN of_IN the_DT rats_NNS ._. Histological_NNP
          inspection_NN of_IN the_DT stained_JJ sections_NNS allowed_VBD an_DT estimation_NN
          of_IN the_DT proportion_NN of_IN transduced_JJ liver_NN cells_NNS ._. Animals_NNS were_VBD
          sacrificed_JJ after_IN 2_CD days_NNS ,_, liver_NN sections_NNS were_VBD prepared_VBN and_CC
          stained_JJ with_IN X-_NNP gal_NN ._. The_DT liver_NN sections_NNS revealed_VBD an_DT
          inhomogeneous_JJ distribution_NN of_IN transduced_JJ cells_NNS ._. In_IN both_DT
          rat_NN strains_NNS hepatocytes_NNS were_VBD the_DT sole_JJ cell_NN type_NN
          expressing_VBG the_DT β-_NN Galactosidase_NNP ._. Both_DT the_DT number_NN of_IN
          stained_JJ cells_NNS and_CC the_DT staining_VBG intensity_NN was_VBD highest_JJS near_IN
          the_DT interlobular_NN (_( portal_NN )_) vein_NN and_CC declined_VBD gradually_RB
          towards_IN the_DT centro_NN lobular_NN area_NN (_( Fig_NNP ._. 5_LS )_) ._. The_DT percentage_NN
          of_IN blue_JJ nuclei_NN was_VBD roughly_RB proportional_JJ to_TO the_DT amount_NN of_IN
          infectious_JJ units_NNS administered_VBN and_CC did_VBD not_RB differ_VB
          significantly_RB between_IN the_DT two_CD strains_NNS (_( Table_NNP 2_LS )_) ._. However_RB ,_,
          overall_JJ ,_, the_DT intensity_NN of_IN the_DT nuclear_JJ LacZ_NNP stain_VB was_VBD 8_CD to_TO
          9_CD times_NNS higher_JJR in_IN the_DT Brown_NNP Norway_NNP than_IN in_IN Wag_NNP /_NN Rij_NNP liver_NN
          sections_NNS as_IN determined_VBN by_IN computer-assisted_JJ analysis_NN of_IN
          the_DT histological_JJ section_NN (_( Fig_NNP ._. 6_CD )_) ._. These_DT findings_NNS suggest_VBP
          that_IN although_IN the_DT protein_NN production_NN is_VBZ significantly_RB
          higher_JJR in_IN the_DT Brown_NNP Norway_NNP rats_NNS ,_, the_DT number_NN of_IN infected_JJ
          cells_NNS is_VBZ roughly_RB similar_JJ for_IN both_DT rat_NN strains_NNS ._. Still_RB the_DT
          number_NN of_IN infectious_JJ particles_NNS per_IN hepatocytes_NNS might_MD be_VB
          higher_JJR in_IN the_DT Brown_NNP Norway_NNP rats_NNS ._. However_RB the_DT number_NN of_IN iu_NN
          can_MD never_RB be_VB 10_CD time_NN higher_JJR because_IN that_DT would_MD require_VB at_IN
          least_JJS 10_CD ×_NN the_DT number_NN of_IN hepatocytes_NNS (_( 1_CD ._. 8_CD 10_CD 9_CD )_) =_SYM 1_CD ._. 8_CD 10_CD
          10_CD ,_, and_CC the_DT dose_NN administered_VBN was_VBD 10_CD 10_CD iu_NN ._.
        
        
          The_DT number_NN of_IN recombinant_JJ adenovirus_JJ copies_NNS in_IN the_DT
          liver_NN
          Real-time_NNP PCR_NNP was_VBD employed_VBN to_TO quantify_VB the_DT copy_NN number_NN
          of_IN the_DT adenoviral_NN genome_NN in_IN the_DT hepatocytes_NNS of_IN rats_NNS from_IN
          the_DT previously_RB described_VBN experiments_NNS that_WDT received_VBD graded_JJ
          doses_NNS of_IN Ad_NN 5_CD Adapt_NNP Luc_NNP ,_, or_CC of_IN Ad_NN 5_CD Adapt_NNP LacZ_NNP ._. As_IN listed_VBN
          in_IN Table_NNP 3_CD ,_, the_DT number_NN of_IN adenoviral_NN copies_NNS per_IN liver_NN was_VBD
          similar_JJ in_IN the_DT Brown_NNP Norway_NNP and_CC Wag_NNP /_NN Rij_NNP rats_NNS for_IN both_DT
          vectors_NNS ._. Roughly_RB ,_, there_EX is_VBZ a_DT linear_JJ relation_NN between_IN the_DT
          Ad_NN 5_CD DNA_NNP detected_VBD and_CC the_DT dose_NN of_IN adenoviral_NN vector_NN
          administered_VBN ._. In_IN the_DT case_NN of_IN LacZ_NNP ,_, the_DT deviation_NN from_IN the_DT
          linearity_NN is_VBZ not_RB statistically_RB significant_JJ ._.
          These_DT results_NNS shows_VBZ that_IN recombinant_JJ Ad_NN 5_CD infect_NN
          hepatocytes_NNS of_IN both_DT rat_NN strains_NNS with_IN similar_JJ
          efficiencies_NNS ._. Thus_RB ,_, the_DT observed_VBD differences_NNS in_IN levels_NNS of_IN
          vector_NN encoded_JJ protein_NN must_MD be_VB due_JJ to_TO differences_NNS in_IN
          transcription_NN (_( CMV-promoter_NNP activity_NN )_) ,_, RNA_NNP stability_NN ,_, RNA_NNP
          translation_NN ,_, or_CC post_NN translational_NN processes_NNS ._.
        
        
          Liver_NNP damage_NN
          Considering_VBG that_IN the_DT local_JJ inflammation_NN of_IN the_DT liver_NN
          may_MD significantly_RB increase_VB the_DT synthesis_NN of_IN certain_JJ
          proteins_NNS ,_, it_PRP could_MD be_VB that_IN the_DT difference_NN in_IN transgene_NN
          expression_NN observed_VBD is_VBZ a_DT consequence_NN of_IN different_JJ
          inflammatory_JJ reactions_NNS in_IN the_DT two_CD strains_NNS ._. To_TO eliminate_VB
          the_DT possibility_NN that_IN the_DT difference_NN found_VBD in_IN the_DT Brown_NNP
          Norway_NNP rats_NNS in_IN encoded_JJ protein_NN is_VBZ due_JJ to_TO a_DT global_JJ
          increase_NN in_IN protein_NN synthesis_NN ,_, the_DT total_JJ amount_NN of_IN liver_NN
          protein_NN was_VBD determined_VBN after_IN different_JJ vector_NN doses_NNS and_CC
          time_NN points_NNS ._. It_PRP was_VBD found_VBN to_TO be_VB similar_JJ in_IN both_DT strains_NNS
          and_CC not_RB significantly_RB elevated_VBD from_IN the_DT basal_NN line_NN (_( Table_NNP
          5_LS )_) ._.
          Adenovirus_NNP particles_NNS in_IN apoptotic_JJ hepatocytes_NNS or_CC
          phagocytosed_JJ by_IN immune_JJ cells_NNS would_MD not_RB contribute_VB to_TO the_DT
          luciferase_NN production_NN ._. However_RB ,_, to_TO exclude_VB that_IN a_DT massive_JJ
          hepatitis_NN or_CC a_DT severe_JJ inflammatory_JJ infiltrate_VB in_IN the_DT
          liver_NN is_VBZ causing_VBG the_DT difference_NN of_IN luciferase_NN expression_NN ,_,
          the_DT inflammatory_JJ infiltration_NN and_CC pathological_JJ changes_NNS
          were_VBD determined_VBN in_IN the_DT liver_NN of_IN the_DT two_CD rat_NN strains_NNS
          (_( Table_NNP 5_LS )_) ._. The_DT damage_NN scoring_VBG shows_VBZ that_IN there_EX is_VBZ no_DT
          difference_NN of_IN toxicity_NN or_CC infiltration_NN 2_CD days_NNS after_IN
          vector_NN delivery_NN and_CC that_IN the_DT difference_NN in_IN transgene_NN
          expression_NN persisted_VBD even_RB when_WRB a_DT low_JJ dose_NN of_IN adenovirus_JJ
          that_WDT caused_VBD hardly_RB any_DT inflammation_NN was_VBD injected_VBN ._. At_IN 7_CD
          days_NNS after_IN the_DT injection_NN ,_, the_DT Brown_NNP Norway_NNP rats_NNS showed_VBD a_DT
          significant_JJ higher_JJR liver_NN damage_NN and_CC infiltration_NN than_IN the_DT
          Wag_NNP /_NN Rij_NNP rats_NNS ._. However_RB ,_, this_DT deviation_NN of_IN the_DT toxicity_NN
          between_IN the_DT two_CD strains_NNS was_VBD not_RB accompanied_VBN by_IN an_DT
          increase_NN in_IN the_DT difference_NN of_IN transgene_NN expression_NN ._.
          Seemingly_NNP ,_, the_DT difference_NN in_IN transgene_NN expression_NN ,_, seen_VBN 2_CD
          days_NNS as_RB well_RB as_IN 7_CD days_NNS after_IN vector_NN administration_NN ,_, is_VBZ
          due_JJ to_TO processes_VBZ that_WDT occur_VBP after_IN the_DT penetration_NN of_IN the_DT
          virus_NN into_IN the_DT cells_NNS ._.
        
        
          Northern_NNP Blotting_NNP of_IN the_DT Luciferase_NNP
          transcript_NN
          To_TO investigate_VB whether_IN an_DT intrinsic_JJ difference_NN exists_VBZ
          in_IN transcription_NN efficiency_NN or_CC in_IN translation_NN efficiency_NN ,_,
          the_DT amount_NN of_IN the_DT luciferase_NN mRNA_NN present_JJ in_IN the_DT liver_NN of_IN
          rats_NNS was_VBD determined_VBN after_IN administration_NN of_IN 10_CD 10_CD iu_NN Ad_NN 5_CD
          Adapt_NNP Luc_NNP intravenously_RB ._. As_IN depicted_VBN in_IN Fig_NNP ._. 7_CD ,_, the_DT
          northern_JJ blot_NN of_IN the_DT liver_NN RNA_NNP shows_VBZ about_IN 10_CD times_NNS more_JJR
          luciferase_NN mRNA_NN in_IN the_DT liver_NN of_IN the_DT Brown_NNP Norway_NNP rats_NNS
          than_IN in_IN the_DT Wag_NNP /_NN Rij_NNP rats_NNS ._. These_DT findings_NNS leave_VBP open_JJ
          only_RB two_CD options_NNS to_TO explain_VB the_DT difference_NN in_IN protein_NN
          levels_NNS observed_VBD ,_, namely_RB an_DT intrinsic_JJ difference_NN in_IN
          transcription_NN efficiency_NN (_( under_IN the_DT CMV_NNP promoter_NN )_) or_CC a_DT
          difference_NN in_IN RNA_NNP stability_NN ._.
        
      
      
        Discussion_NNP
        It_PRP has_VBZ been_VBN suggested_VBN that_IN ,_, after_IN iv_NN administration_NN ,_, low_JJ
        dose_NN intravenous_JJ adenoviral_NN vectors_NNS are_VBP taken_VBN up_RP by_IN Kupffer_NNP
        cells_NNS and_CC degraded_JJ quickly_RB within_IN a_DT few_JJ hours_NNS [_NN 1_CD 9_CD ]_NN
        whereas_IN higher_JJR doses_NNS saturate_VB these_DT cells_NNS and_CC the_DT surplus_NN
        productively_RB transduce_NN hepatocytes_NNS ._. Therefore_RB ,_, we_PRP used_VBD
        doses_NNS (_( 10_CD 9_CD iu_NN -_: 10_CD 10_CD iu_NN )_) that_WDT are_VBP in_IN the_DT linear_JJ part_NN of_IN the_DT
        dose_NN response_NN curve_NN and_CC well_RB above_IN the_DT threshold_NN effect_NN ._. In_IN
        both_DT rat_NN strains_NNS ,_, 2_CD days_NNS after_IN intravenous_JJ delivery_NN of_IN the_DT
        vector_NN ,_, the_DT β-_NN Galactosidase_NNP was_VBD observed_VBN only_RB in_IN the_DT
        hepatocytes_NNS ._. Consequently_RB ,_, it_PRP may_MD be_VB concluded_VBN that_IN the_DT
        bulk_NN of_IN the_DT adenoviral_NN genomes_NNS in_IN the_DT liver_NN is_VBZ localized_VBN in_IN
        the_DT hepatocytes_NNS ._.
        After_IN correction_NN for_IN the_DT extraction_NN efficiency_NN of_IN DNA_NNP ,_,
        an_DT average_NN of_IN 2_CD ._. 6_CD 10_CD 9_CD copies_NNS of_IN vector_NN genome_NN were_VBD detected_VBN
        in_IN the_DT livers_NNS following_VBG administration_NN of_IN 10_CD 10_CD iu_NN Ad_NN 5_CD Adapt_NNP
        LacZ_NNP ._. At_IN this_DT dose_NN 75_CD %_NN of_IN the_DT hepatocytes_NNS stained_JJ positive_NN
        for_IN β-_NN Galactosidase_NNP ._. It_PRP is_VBZ estimated_VBN that_IN the_DT liver_NN of_IN a_DT
        350_CD g_SYM rat_NN contains_VBZ about_IN 1_CD ._. 8_CD 10_CD 9_CD hepatocytes_NNS [_NN 10_CD ]_NN ._. Thus_RB
        the_DT average_JJ number_NN of_IN infectious_JJ units_NNS per_IN hepatocyte_NN is_VBZ
        about_IN 1_CD ._. 5_CD ._. It_PRP is_VBZ assumed_VBN that_IN the_DT infection_NN of_IN hepatocytes_NNS
        by_IN the_DT adenoviruses_NNS is_VBZ a_DT random_JJ event_NN following_VBG the_DT Poisson_NNP
        distribution_NN ._. Then_RB ,_, this_DT event_NN will_MD occur_VB at_IN least_JJS one_CD time_NN
        in_IN 75_CD %_NN of_IN the_DT cases_NNS when_WRB the_DT expected_VBN number_NN of_IN occurrences_NNS
        is_VBZ 1_CD ._. 5_CD ._. As_IN about_IN 75_CD %_NN of_IN the_DT hepatocytes_NNS stained_JJ blue_JJ
        following_NN injection_NN of_IN 10_CD 10_CD iu_NN ,_, an_DT hepatocyte_NN will_MD stain_VB
        blue_JJ if_IN it_PRP has_VBZ incorporated_VBN one_CD copy_NN of_IN the_DT vector_NN ._. Poisson_NNP
        probability_NN calculations_NNS show_VBP also_RB that_IN under_IN these_DT
        conditions_NNS the_DT infection_NN occurs_VBZ twice_RB in_IN 40_CD %_NN and_CC three_CD
        times_NNS in_IN 20_CD %_NN of_IN the_DT hepatocytes_NNS ._. This_DT variation_NN in_IN the_DT
        number_NN of_IN adenoviral_NN copies_NNS per_IN cell_NN can_MD explain_VB the_DT
        variation_NN of_IN the_DT staining_VBG intensity_NN per_IN cell_NN within_IN one_CD
        liver_NN ,_, from_IN light_JJ to_TO dark_JJ blue_NN ._.
        In_IN each_DT of_IN the_DT vectors_NNS used_VBN in_IN this_DT study_NN the_DT transgene_NN
        was_VBD under_IN the_DT control_NN of_IN the_DT CMV_NNP immediate_JJ early_JJ promoter_NN ._.
        It_PRP was_VBD determined_VBN ,_, by_IN Norther_NNP Blots_NNP ,_, that_IN the_DT amount_NN of_IN
        transgenic_JJ mRNA_NN was_VBD also_RB different_JJ in_IN both_DT rat_NN strains_NNS ._.
        Thus_RB ,_, the_DT difference_NN in_IN vector_NN encoded_JJ protein_NN production_NN
        found_VBD is_VBZ due_JJ to_TO difference_NN in_IN transgene_NN transcription_NN or_CC
        difference_NN in_IN RNA_NNP stability_NN ._.
        As_IN expected_VBN ,_, a_DT difference_NN in_IN protein_NN levels_NNS was_VBD observed_VBN
        following_VBG 3_CD different_JJ doses_NNS of_IN the_DT vector_NN 10_CD 9_CD ,_, 3_CD 10_CD 9_CD and_CC
        10_CD 10_CD iu_NN ._. However_RB ,_, the_DT lower_VB the_DT dose_NN ,_, the_DT smaller_JJR is_VBZ the_DT
        difference_NN of_IN protein_NN expression_NN between_IN the_DT two_CD rat_NN
        strains_NNS ._. This_DT might_MD be_VB explained_VBN by_IN a_DT saturation_NN of_IN the_DT
        transgene_NN expression_NN machinery_NN in_IN the_DT Wag_NNP /_NN Rij_NNP hepatocytes_NNS
        at_IN the_DT higher_JJR doses_NNS ._.
        The_DT different_JJ protein_NN expression_NN in_IN Wag_NNP /_NN Rij_NNP and_CC Brown_NNP
        Norway_NNP rats_NNS was_VBD observed_VBN with_IN 4_CD different_JJ transgenes_NNS
        (_( Luciferase_NNP ,_, β-_NN Galactosidase_NNP ,_, endostatin_NN and_CC mhATF-BPTI_JJ )_)
        and_CC at_IN several_JJ different_JJ doses_NNS ._. Our_PRP$ experiments_NNS localised_JJ
        the_DT mechanism_NN of_IN this_DT difference_NN at_IN the_DT transcriptional_NN
        level_NN and_CC disqualified_VBN the_DT hypothesis_NNS based_VBN on_IN
        immunological_JJ induced_VBN death_NN of_IN the_DT infected_JJ cells_NNS ._.
        Nevertheless_RB ,_, the_DT differences_NNS of_IN transcription_NN efficiency_NN
        observed_VBD between_IN the_DT two_CD rat_NN strains_NNS might_MD be_VB due_JJ to_TO
        different_JJ cytokine_NN production_NN following_VBG the_DT adenoviral_NN
        infection_NN ._. It_PRP was_VBD shown_VBN that_IN the_DT adenoviral_NN infection_NN of_IN
        the_DT liver_NN activates_NNS the_DT innate_JJ immunity_NN with_IN increase_NN NK_NNP
        cells_NNS and_CC cytokines_NNS production_NN (_( INF-γ_NNP ,_, TNF-α_NNP ,_, IL-_NNP 12_CD ,_, IL-_NNP 6_CD )_)
        [_NN 11_CD 12_CD 13_CD 14_CD ]_NN ._. Further_RB ,_, differences_NNS of_IN this_DT activation_NN
        between_IN mouse_NN strains_NNS were_VBD associated_VBN with_IN variation_NN in_IN
        adenovirus_JJ transgene_NN expression_NN [_NN 11_CD 13_CD ]_NN ._. However_RB it_PRP was_VBD
        demonstrated_VBN that_IN no_DT activation_NN of_IN the_DT innate_JJ immunity_NN and_CC
        that_IN no_DT difference_NN of_IN transgene_NN expression_NN could_MD be_VB
        observed_VBN before_IN the_DT seventh_JJ day_NN after_IN the_DT adenoviral_NN
        administration_NN [_NN 13_CD ]_NN ._. Furthermore_RB the_DT decrease_NN of_IN
        transgene_NN expression_NN after_IN activation_NN of_IN the_DT innate_JJ
        immunity_NN following_VBG i_NNP ._. v_NN ._. administration_NN of_IN adenovirus_JJ was_VBD
        due_JJ to_TO decrease_NN of_IN the_DT number_NN of_IN infected_JJ cells_NNS and_CC a_DT
        corresponding_JJ diminution_NN of_IN the_DT viral_JJ DNA_NNP in_IN the_DT liver_NN [_NN 15_CD
        ]_NN ._. Our_PRP$ results_NNS do_VBP not_RB show_VB such_JJ results_NNS ._. However_RB ,_, in_IN such_JJ
        perspective_NN we_PRP measured_VBD the_DT serum_NN level_NN of_IN INF-γ_NNP in_IN both_DT
        rat_NN strains_NNS 2_CD days_NNS after_IN the_DT vector_NN administration_NN and_CC no_DT
        difference_NN could_MD be_VB observed_VBN (_( 60_CD ±_NN 14_CD pg_NN /_NN ml_NN in_IN the_DT
        Wag_NNP /_NN Rij_NNP rats_NNS versus_CC 65_CD ±_NN 18_CD pg_NN /_NN ml_NN in_IN the_DT Brown_NNP Norway_NNP
        rats_NNS )_) ._. Nevertheless_RB ,_, difference_NN of_IN intracellular_NN cytokine_NN
        response_NN to_TO the_DT adenoviral_NN infection_NN might_MD explain_VB the_DT
        difference_NN in_IN transcription_NN efficiency_NN ._.
        In_IN general_JJ ,_, differences_NNS between_IN inbred_JJ strains_NNS are_VBP
        considered_VBN to_TO reflect_VB differences_NNS between_IN individual_JJ
        members_NNS of_IN outbred_JJ species_NNS ._. If_IN the_DT variation_NN observed_VBD in_IN
        the_DT rat_NN strains_NNS described_VBD here_RB would_MD hold_VB for_IN individual_JJ
        humans_NNS ,_, the_DT therapeutic_JJ efficiency_NN of_IN gene_NN transfer_NN could_MD
        drastically_RB vary_VB from_IN one_CD patient_NN to_TO another_DT after_IN systemic_JJ
        administration_NN of_IN adenoviral_NN vectors_NNS ._.
      
      
        Methods_NNP
        
          Animals_NNS
          Pathogen-free_NNP inbred_JJ male_JJ Wag_NNP /_NN Rij_NNP and_CC Brown_NNP Norway_NNP
          rats_NNS ,_, weighing_VBG 300_CD to_TO 350_CD gr_NN were_VBD purchased_VBN from_IN Harlan_NNP ,_,
          The_DT Netherlands_NNP ._. All_DT animals_NNS were_VBD fed_VBN ad_NN libitum_NN with_IN
          laboratory_NN chow_NN and_CC water_NN and_CC were_VBD kept_VBN under_IN standard_JJ
          laboratory_NN conditions_NNS ._. For_IN assay_NN of_IN plasma_NN transaminase_NN
          (_( ALT_NNP )_) ,_, hEndostatin_NN ,_, and_CC mhATF-BPTI_JJ ,_, rats_NNS were_VBD
          anaesthetised_JJ with_IN isoflurane_NN and_CC bled_VBD by_IN tail_NN vein_NN
          puncture_NN and_CC the_DT blood_NN was_VBD collected_VBN in_IN EDTA_NNP tubes_NNS ._. All_DT
          animal_NN procedures_NNS were_VBD performed_VBN in_IN accordance_NN with_IN the_DT
          official_JJ guidelines_NNS after_IN obtaining_VBG permission_NN of_IN the_DT
          animal_NN welfare_NN committee_NN ._. Measurements_NNP of_IN ALT_NNP were_VBD
          performed_VBN according_VBG to_TO standard_JJ clinical_JJ procedures_NNS ._.
        
        
          Adenoviral_NNP vectors_NNS
          Recombinant_NNP adenovirus_JJ vectors_NNS were_VBD generated_VBN in_IN
          PER_NNP ._. C_NNP 6_CD ™_NN cells_NNS by_IN homologous_RB recombination_NN between_IN an_DT
          adapter_NN plasmid_NN (_( pAdapt_NN )_) and_CC the_DT E_NNP 1_CD deleted_VBN Ad_NN 5_CD DNA_NNP
          plasmid_NN as_IN described_VBN elsewhere_RB [_NN 16_CD ]_NN ._. The_DT expression_NN
          cassette_NN contains_VBZ a_DT CMV_NNP promoter_NN and_CC SV_NNP 40_CD poly_RB A_DT signal_NN ._.
          As_IN a_DT result_NN of_IN the_DT absence_NN of_IN sequence_NN overlap_VB between_IN
          the_DT Adapt_NNP plasmid_NN and_CC the_DT Ad_NN 5_CD E_NNP 1_CD sequences_NNS integrated_VBN
          into_IN the_DT genome_NN of_IN PER_NNP ._. C_NNP 6_CD ,_, the_DT vector_NN stocks_NNS used_VBN in_IN this_DT
          study_NN did_VBD not_RB contain_VB replicative_JJ competent_JJ adenovirus_JJ
          (_( RCA_NNP )_) [_NN 17_CD ]_NN ._.
          The_DT Ad_NN 5_CD Adapt_NNP mhAB_NN encodes_NNS for_IN a_DT murinised_JJ form_NN of_IN the_DT
          human_JJ ATF-BPTI_NNP (_( mhAB_NN )_) [_NN 18_CD ]_NN ._. In_IN this_DT construct_VB the_DT
          mhATF-BPTI_JJ ,_, is_VBZ preceded_VBN by_IN the_DT native_JJ secretion_NN signal_NN
          peptide_NN of_IN the_DT human_JJ urokinase_NN ._. The_DT human_JJ endostatin_NN
          coding_VBG sequence_NN (_( InvivoGen_NNP ,_, CA_NNP ,_, USA_NNP )_) was_VBD cloned_VBN in_IN the_DT
          Ad_NN 5_CD Adapt_NNP shuttle_NN vector_NN ._. The_DT encoded_JJ endostatin_NN
          corresponds_NNS to_TO the_DT 183_CD residue_NN of_IN the_DT human_JJ endostatin_NN
          described_VBN by_IN O_NNP '_POS Reilly_NNP et_CC al_NN (_( 1997_CD )_) with_IN an_DT intact_JJ
          N-_NNP terminus_JJ (_( HSHRDFQ_NNP ._. ._. ._. )_) ,_, preceded_VBN by_IN the_DT secretion_NN signal_NN
          peptide_NN of_IN the_DT human_JJ IL-_NNP 2_CD ._. The_DT Ad_NN ._. Adapt_NNP ._. Luc_NNP and_CC the_DT
          Ad_NN ._. Adapt_NNP ._. LacZ_NNP are_VBP recombinant_JJ adenoviral_NN vectors_NNS in_IN which_WDT
          the_DT E_NNP 3_CD region_NN of_IN Ad_NN 5_CD is_VBZ retained_VBN and_CC the_DT gene_NN of_IN interest_NN
          (_( luciferase_NN or_CC LacZ_NNP )_) replaces_VBZ the_DT E_NNP 1_CD region_NN ._. The_DT Ad_NN 5_CD
          Adapt_NNP empty_JJ is_VBZ identical_JJ to_TO Ad_NN 5_CD Adapt_NNP mhAB_NN except_IN that_IN it_PRP
          does_VBZ not_RB encode_NN any_DT transgene_NN ._.
          All_DT vectors_NNS were_VBD produced_VBN on_IN PER_NNP ._. C_NNP 6_CD ™_NN using_VBG standard_JJ
          procedures_NNS [_NN 17_CD ]_NN ._. Infectious_NNP units_NNS (_( iu_NN )_) /_NN ml_NN were_VBD
          determined_VBN by_IN end_NN point_NN cytopathogenic_JJ effect_NN (_( CPE_NNP )_) assay_NN
          on_IN 911_CD cells_NNS [_NN 19_CD ]_NN ._. Viral_NNP particles_NNS were_VBD determined_VBN by_IN
          HPLC_NNP [_NN 20_CD ]_NN ._. The_DT particle_NN to_TO infectious_JJ unit_NN ratio_NN was_VBD
          always_RB lower_JJR than_IN 10_CD ._. A_DT single_JJ batch_NN per_IN vector_NN was_VBD used_VBN
          in_IN all_DT experiments_NNS ._.
        
        
          Liver_NNP lysate_NN and_CC Luciferase_NNP activity_NN assay_NN
          Rats_NNP were_VBD sacrificed_JJ by_IN an_DT overdose_NN of_IN isoflurane_NN and_CC
          whole_JJ organs_NNS were_VBD dissected_VBN out_IN ,_, frozen_VBN in_IN liquid_JJ
          nitrogen_NN and_CC stored_VBD at_IN -_: 80_CD °_NN C_NNP ._. Organs_NNP were_VBD homogenised_JJ in_IN
          phosphate_NN buffered_JJ saline_NN pH_NN 7_CD ._. 8_CD using_VBG a_DT blender_NN ._. To_TO lyse_NN
          the_DT cells_NNS ,_, DTT_NNP (_( SIGMA_NNP ,_, The_DT Netherlands_NNP )_) (_( 1_CD mM_NN )_) and_CC Triton_NNP
          x-_NN 100_CD (_( 0_CD ._. 1_LS %_NN )_) (_( Merck_NNP ,_, The_DT Netherlands_NNP )_) were_VBD added_VBN ._. After_IN
          centrifugation_NN at_IN 10_CD ,_, 000_CD rpm_NN for_IN 10_CD min_NN ,_, 20_CD μl_NN of_IN the_DT
          supernatant_NN was_VBD added_VBN to_TO 100_CD μl_NN of_IN luciferase_NN assay_NN
          substrate_NN (_( Promega_NNP ,_, The_DT Netherlands_NNP )_) ._. Relative_NNP light_JJ
          units_NNS (_( RLU_NNP )_) were_VBD determined_VBN for_IN 30_CD s_VBZ using_VBG a_DT luminometer_NN
          (_( Lumat_NNP 951_CD ,_, Wallac_NNP ,_, Belgium_NNP )_) ._. The_DT amount_NN of_IN protein_NN in_IN
          the_DT extracts_NNS was_VBD determined_VBN using_VBG a_DT commercial_JJ kit_NN
          (_( Bio-_NNP Rad_NNP laboratories_NNS ,_, The_DT Netherlands_NNP )_) based_VBN on_IN the_DT
          Coomasie_NNP brilliant_JJ blue_JJ G_NNP 250_CD binding_JJ assay_NN developed_VBN by_IN
          Bradford_NNP [_NN 21_CD ]_NN ._. The_DT level_NN of_IN luciferase_NN activity_NN in_IN the_DT
          tissue_NN homogenates_NNS was_VBD expressed_VBN in_IN RLU_NNP /_NN mg_NN protein_NN ._. The_DT
          background_NN level_NN of_IN this_DT assay_NN is_VBZ <_NN 1000_CD RLU_NNP /_NN mg_NN protein_NN
          and_CC was_VBD defined_VBN by_IN measuring_VBG luciferase_NN activity_NN in_IN
          organs_NNS of_IN non_NN treated_VBD rats_NNS ._.
        
        
          LacZ_NNP expression_NN assay_NN
          Forty-eight_NNP hours_NNS after_IN Ad_NN 5_CD Adapt_NNP LacZ_NNP administration_NN
          rats_NNS were_VBD sacrificed_JJ and_CC organs_NNS were_VBD removed_VBN and_CC cut_VB in_IN 2_CD
          mm_NN sections_NNS ._. Sections_NNP were_VBD fixed_VBN in_IN 10_CD %_NN phosphate_NN
          buffered_JJ formalin_NN (_( pH_NN 7_CD ._. 0_CD )_) for_IN 60_CD min_NN at_IN room_NN temperature_NN
          and_CC incubated_JJ overnight_JJ in_IN 0_CD ._. 5_CD M_NNP sucrose_NN ._. The_DT samples_NNS
          were_VBD subsequently_RB frozen_VBN in_IN liquid_JJ nitrogen_NN ._. Ten_CD μm_NN thick_JJ
          frozen_VBN sections_NNS were_VBD prepared_VBN and_CC stained_JJ with_IN
          5_CD -_: bromo-_NN 4_CD -_: chloro-_NN 3_CD -_: indolyl-β-galactopyranoside_JJ (_( X-_NNP gal_NN )_)
          solution_NN (_( Molecular_NNP Probes_NNP ,_, The_DT Netherlands_NNP )_) overnight_JJ at_IN
          37_CD °_NN C_NNP ._. Finally_RB ,_, sections_NNS were_VBD counterstained_JJ with_IN
          Hematoxylin-_NNP Phloxin-_NNP Safran_NNP ._. The_DT number_NN of_IN blue_JJ nuclei_NN in_IN
          each_DT section_NN was_VBD determined_VBN on_IN digitalised_JJ photographs_NNS of_IN
          four_CD 20_CD ×_NN magnification_NN fields_NNS with_IN the_DT interlobular_NN vein_NN
          in_IN the_DT centre_NN (_( designated_VBN portal_NN area_NN )_) and_CC of_IN four_CD fields_NNS
          centred_JJ on_IN the_DT central_JJ vein_NN (_( called_VBN centro-lobular_JJ area_NN )_) ._.
          These_DT two_CD areas_NNS were_VBD slightly_RB overlapping_VBG ._. The_DT resolution_NN
          of_IN the_DT photographs_NNS ,_, which_WDT were_VBD processed_VBN in_IN Adobe_NNP
          Photoshop_NNP 5_CD ._. 0_CD ,_, was_VBD 600_CD dots_NNS per_IN inch_NN (_( dpi_NN )_) ._. Cells_NNP were_VBD
          considered_VBN positive_JJ when_WRB a_DT blue_JJ staining_VBG was_VBD seen_VBN in_IN the_DT
          nucleus_NN ._. The_DT total_JJ number_NN of_IN hepatocytes_NNS per_IN field_NN was_VBD
          determined_VBN by_IN dividing_VBG the_DT surface_NN of_IN the_DT tissue_NN section_NN
          by_IN the_DT average_JJ surface_NN of_IN a_DT hepatocyte_NN ._. The_DT surface_NN of_IN
          the_DT lumen_NN of_IN large_JJ vessels_NNS was_VBD subtracted_VBN from_IN the_DT total_JJ
          surface_NN of_IN the_DT tissue_NN section_NN ._. The_DT average_JJ surface_NN of_IN the_DT
          hepatocytes_NNS was_VBD determined_VBN by_IN ten_CD measurements_NNS of_IN
          mononuclear_NN hepatocytes_NNS per_IN field_NN ._. The_DT surface_NN
          measurements_NNS were_VBD performed_VBN with_IN the_DT NIH_NNP Image_NN 1_CD ._. 62_CD
          software_NN ._. It_PRP was_VBD shown_VBN in_IN rats_NNS that_WDT binuclear_NN hepatocytes_NNS
          have_VBP double_VB the_DT volume_NN of_IN mononuclear_NN hepatocytes_NNS and_CC
          that_IN the_DT extrahepatocytic_JJ space_NN volume_NN was_VBD 15_CD %_NN of_IN the_DT
          total_JJ liver_NN volume_NN [_NN 10_CD ]_NN ._.
          To_TO compare_VB β-_NN Galactosidase_NNP expression_NN levels_NNS in_IN the_DT
          livers_NNS of_IN Wag_NNP /_NN Rij_NNP and_CC Brown_NNP Norway_NNP rats_NNS ,_, frozen_VBN livers_NNS
          were_VBD cut_VBN into_IN sections_NNS with_IN a_DT thickness_NN of_IN 5_CD ,_, 10_CD ,_, 15_CD ,_, 20_CD ,_,
          25_CD ,_, 30_CD ,_, 35_CD ,_, 40_CD ,_, 45_CD and_CC 50_CD μm_NN ._. Whole_JJ sections_NNS were_VBD scanned_JJ
          at_IN 600_CD dpi_NN under_IN TIFF_NNP format_NN and_CC analysed_JJ in_IN Adobe_NNP
          Photoshop_NNP 6_CD ._. 0_CD ._. We_PRP quantified_VBN the_DT blue_JJ staining_VBG intensity_NN
          by_IN performing_VBG the_DT histogram_NN of_IN the_DT luminosity_NN and_CC of_IN the_DT
          four_CD colours_NNS on_IN the_DT whole_JJ liver_NN section_NN ._. Matching_NNP the_DT
          histograms_NNS of_IN a_DT Brown_NNP Norway_NNP section_NN to_TO a_DT Wag_NNP /_NN Rij_NNP section_NN
          with_IN different_JJ thickness_NN determine_VBP the_DT relative_JJ liver_NN
          β-_NN Galactosidase_NNP intensity_NN of_IN the_DT two_CD strains_NNS ._.
        
        
          Elisa_NNP assays_NNS
          An_DT mhATF-BPTI_JJ enzyme-linked_JJ immunoabsorbent_NN assay_NN
          (_( ELISA_NNP )_) was_VBD developed_VBN by_IN Dr_NNP ._. P_NN ._. Quax_NNP (_( Toegepast_NNP
          Natuurwetenschappelijk_NNP Onderzoek_NNP institute_NN )_) ,_, using_VBG a_DT
          monoclonal_NN antibody_NN specific_JJ for_IN the_DT ATF_NNP as_IN the_DT capture_NN
          antibody_NN and_CC a_DT polyclonal_NN antibody_NN directed_VBN against_IN BPTI_NNP
          as_IN the_DT detector_NN antibody_NN [_NN 18_CD ]_NN ._. As_IN a_DT standard_JJ we_PRP used_VBD
          medium_NN of_IN Ad_NN 5_CD Adapt_NNP mhAB_NN infected_JJ CHO_NNP cell_NN culture_NN in_IN
          which_WDT the_DT mhATF-BPTI_JJ concentration_NN was_VBD determined_VBN by_IN an_DT
          urokinase_NN ELISA_NNP ._. Secretion_NNP of_IN human_JJ endostatin_NN in_IN plasma_NN
          was_VBD routinely_RB determined_VBN using_VBG a_DT commercial_JJ ELISA_NNP kit_NN
          (_( InvivoGen_NNP ,_, CA_NNP ,_, USA_NNP )_) according_VBG to_TO the_DT manufacturer_NN
          procedure_NN ._. INF-γ_NNP levels_NNS in_IN rat_NN sera_NN were_VBD measured_VBN by_IN an_DT
          ELISA_NNP kit_NN (_( BioSource_NNP Netherlands_NNP ,_, B_NNP ._. V_NNP ._. ,_, The_DT
          Netherlands_NNP )_) ._.
        
        
          Real_NNP Time_NNP PCR_NNP analysis_NN
          The_DT amount_NN of_IN adenoviral_NN genomes_NNS per_IN cell_NN was_VBD
          determined_VBN by_IN a_DT multiplex_NN real-time_JJ polymerase_NN chain_NN
          reaction_NN [_NN 22_CD ]_NN ._. Real-time_NNP PCR_NNP is_VBZ based_VBN on_IN the_DT 5_CD '_POS -_: 3_CD '_POS
          nuclease_NN activity_NN of_IN AmpliTaq_NNP Gold_NNP polymerase_NN ,_, which_WDT
          allows_VBZ it_PRP to_TO cleave_NN fluorogenic_JJ probes_NNS resulting_VBG in_IN
          fluorescence_NN ._. The_DT amount_NN of_IN fluorescence_NN obtained_VBN during_IN
          the_DT PCR_NNP reaction_NN is_VBZ representative_NN to_TO the_DT amount_NN of_IN
          amplified_VBN DNA_NNP ._.
          Total_NNP DNA_NNP of_IN transduced_JJ rat_NN organs_NNS was_VBD extracted_VBN by_IN
          using_VBG a_DT DNeasy_NNP Tissue_NNP Kit_NNP (_( Qiagen_NNP )_) ._. The_DT kit_NN efficiency_NN
          was_VBD verified_VBN by_IN measuring_VBG the_DT recovery_NN of_IN plasmid_NN DNA_NNP
          mixed_JJ from_IN a_DT liver_NN lysate_NN ._. We_PRP confirmed_VBD that_IN 80_CD %_NN of_IN the_DT
          total_JJ DNA_NNP can_MD be_VB extracted_VBN from_IN liver_NN samples_NNS ,_, as_IN
          described_VBN by_IN the_DT manufacturer_NN ._. To_TO amplify_VB the_DT adenoviral_NN
          DNA_NNP ,_, specific_JJ primers_NNS (_( Ad_NN 5_CD Clip-_NNP F_NNP :_: 5_CD '_POS CGACGGATGTGGCAAAAGT_NNP 3_CD '_POS
          and_CC Ad_NN 5_CD Clip-_NNP R_NNP :_: 5_CD '_POS CCTAAAACCGCGCGAAAA_NNP 3_CD '_POS )_) were_VBD designed_VBN by_IN
          using_VBG the_DT Primer_NNP Express_NNP Software_NNP (_( Perkin-_NNP Elmer_NNP ,_, Foster_NNP
          City_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. A_DT fluorogenic_JJ probe_NN (_( Ad_NN 5_CD Clip-_NNP Pr_NNP :_:
          5_CD '_POS -_: VIC-CACCGGCGCACACCAAAAACG-TAMRA-_NNP 3_CD '_POS )_) was_VBD also_RB designed_VBN
          by_IN the_DT Primer_NNP Express_NNP Software_NNP ._. To_TO determine_VB the_DT amount_NN
          of_IN cellular_JJ DNA_NNP present_JJ in_IN the_DT sample_NN a_DT second_JJ pair_NN of_IN
          primers_NNS and_CC a_DT FAM-probe_NNP specific_JJ for_IN 18_CD S_NNP rDNA_NN [_NN 22_CD ]_NN were_VBD
          used_VBN ._. The_DT PCR_NNP reaction_NN mixture_NN consisted_VBD of_IN 1_CD ×_NN buffer_NN A_DT
          (_( Perkin-_NNP Elmer_NNP )_) ,_, 3_CD mM_NN MgCl_NNP 
          2_CD ,_, 200_CD μM_NN dNTPs_NNS ,_, 90_CD nM_NN of_IN each_DT
          adenovirus_JJ primer_NN ,_, 100_CD nM_NN of_IN each_DT 18_CD S_NNP rDNA_NN primer_NN ,_, 200_CD nM_NN
          of_IN each_DT probe_NN ,_, 0_CD ._. 6_CD U_NNP AmpliTaq_NNP Gold_NNP polymerase_NN
          (_( Perkin-_NNP Elmer_NNP )_) and_CC 5_CD μl_NN of_IN total_JJ DNA_NNP sample_NN ._. As_IN a_DT
          standard_NN ,_, to_TO determine_VB the_DT amount_NN of_IN adenoviral_NN genomes_NNS
          and_CC cellular_JJ DNA_NNP ,_, a_DT plasmid_NN containing_VBG approximately_RB 5000_CD
          bp_NN of_IN the_DT left_NN part_NN of_IN the_DT Ad_NN 5_CD genome_NN (_( pAdapt_NN )_) was_VBD mixed_VBN
          with_IN cellular_JJ DNA_NNP extracted_VBD from_IN A_DT 549_CD cells_NNS ._. The_DT PCR_NNP
          reaction_NN was_VBD initiated_VBN with_IN a_DT hot_JJ start_NN at_IN 95_CD °_NN C_NNP for_IN 10_CD
          min_NN and_CC involved_VBN 45_CD cycles_NNS of_IN 15_CD s_VBZ at_IN 95_CD °_NN C_NNP and_CC 1_CD min_NN at_IN
          60_CD °_NN C_NNP ._.
        
        
          Northern_NNP Blotting_NNP
          The_DT animals_NNS were_VBD sacrificed_JJ 2_CD days_NNS after_IN vector_NN
          administration_NN and_CC the_DT liver_NN was_VBD immediately_RB collected_VBN
          and_CC snap_NN frozen_VBN in_IN liquid_JJ nitrogen_NN ._. The_DT liver_NN samples_NNS
          were_VBD cut_VBN and_CC homogenised_JJ in_IN Trizol_NNP reagent_NN (_( Gibco_NNP Life_NNP
          Technologies_NNPS )_) using_VBG a_DT blender_NN ._. Total_NNP RNA_NNP was_VBD isolated_VBN
          from_IN the_DT liver_NN tissue_NN homogenate_NN by_IN using_VBG the_DT method_NN
          developed_VBN by_IN Chomoczynski_NNP and_CC Sacchi_NNP [_NN 23_CD ]_NN ._. Briefly_NNP ,_,
          chloroform_NN was_VBD added_VBN and_CC the_DT aqueous_JJ phase_NN containing_VBG the_DT
          RNA_NNP was_VBD recovered_VBN ._. RNA_NNP was_VBD precipitated_VBD with_IN isopropyl_NN
          alcohol_NN and_CC the_DT pellet_NN was_VBD resuspended_JJ in_IN RNase_NNP free_JJ
          water_NN ._. The_DT RNA_NNP and_CC DNA_NNP content_NN were_VBD measured_VBN by_IN
          spectrophotometric_JJ analysis_NN ._.
          The_DT quantity_NN of_IN RNA_NNP loaded_VBD was_VBD 20_CD μg_NN as_IN determined_VBN by_IN
          spectrophotometry_NN ._. The_DT RNA_NNP loaded_VBD represents_VBZ a_DT similar_JJ
          proportion_NN of_IN luciferase_NN mRNA_NN in_IN both_DT strains_NNS as_IN the_DT
          total_JJ concentrations_NNS of_IN RNA_NNP are_VBP similar_JJ in_IN the_DT Wag_NNP /_NN Rij_NNP
          (_( 6_CD ._. 40_CD ±_NN 1_CD ._. 43_CD μg_NN /_NN gr_NN )_) and_CC in_IN the_DT Brown_NNP Norway_NNP rats_NNS (_( 6_CD ._. 55_CD ±_NN
          1_CD ._. 91_CD μg_NN /_NN gr_NN )_) ._. The_DT RNA_NNP was_VBD run_VBN on_IN a_DT 1_CD %_NN agarose_NN gel_NN and_CC
          transferred_VBN onto_IN Hybond_NNP N_NNP +_NN membrane_NN by_IN overnight_JJ
          transfer_NN ._. The_DT RNA_NNP was_VBD then_RB fixed_VBN by_IN UV_NNP irradiation_NN ._. The_DT
          hybridisation_NN was_VBD performed_VBN overnight_JJ with_IN one_CD stranded_VBN [_NN
          32_CD P_NN ]_NN α-d_JJ ATF_NNP Luciferase_NNP probe_NN (_( 1800_CD bp_NN )_) ._. The_DT membrane_NN was_VBD
          exposed_VBN to_TO a_DT X-_NNP ray_NN film_NN (_( Kodak_NNP )_) for_IN 24_CD h_NN and_CC afterwards_RB
          the_DT membrane_NN was_VBD scanned_JJ in_IN a_DT phosphorimager_NN for_IN
          quantification_NN ._. Then_RB the_DT membrane_NN was_VBD stripped_VBN 15_CD min_NN at_IN
          65_CD °_NN C_NNP and_CC prehybridised_JJ with_IN salmon_NN sperm_NN DNA_NNP ._. Then_RB a_DT
          second_JJ hybridisation_NN procedure_NN was_VBD performed_VBN with_IN the_DT [_NN
          32_CD P_NN ]_NN α-d_JJ ATF_NNP β-actine_JJ probe_NN ._.
        
        
          Pathology_NNP
          The_DT scoring_VBG of_IN the_DT liver_NN damage_NN was_VBD performed_VBN in_IN
          Wag_NNP /_NN Rij_NNP and_CC Brown_NNP Norway_NNP rats_NNS 2_CD and_CC 7_CD days_NNS after_IN the_DT
          intravenous_JJ injection_NN of_IN adenoviral_NN vectors_NNS ._. The_DT liver_NN
          pieces_NNS were_VBD fixed_VBN in_IN formalin_NN 10_CD %_NN ,_, embedded_VBN in_IN paraffin_NN
          and_CC sections_NNS of_IN 10_CD μm_NN were_VBD stained_JJ with_IN haematoxylin_NN and_CC
          eosin_NN ._. The_DT total_JJ damage_NN score_NN is_VBZ a_DT compilation_NN of_IN scores_NNS
          of_IN apoptosis_NNS ,_, vacuolar_NN changes_NNS ,_, nuclear_JJ condensation_NN ,_,
          anisonucleosis_NNS ,_, megalocytosis_NNS ,_, mitosis_NNS ,_, and_CC inflammation_NN
          (_( Table_NNP 4_LS )_) ._.
        
      
      
        List_NN of_IN abbreviations_NNS
        ALAT_NNP :_: Alanin_NNP Amino_NNP Trasferase_NNP
        ATF_NNP :_: Amino_NNP Terminal_NNP Fragment_NNP
        BPTI_NNP :_: Bovine_NNP Pancreatic_NNP Trypsine_NNP Inhibitor_NNP
        γGT_NN :_: Gamma_NNP Glutamyl_NNP Transferease_NNP
        iu_NN :_: Infectious_NNP units_NNS
        IU_NNP :_: International_NNP Units_NNS
        iv_NN :_: Intra_NNP venous_JJ
        LDH_NNP :_: Lactate_NNP DesHydrogenase_NNP
        mhATF-BPTI_JJ :_: Murinised_NNP human_JJ ATF-BPTI_NNP
      
      
        Authors_NNP '_'' Contributions_NNP
        PL_NNP and_CC JA_NNP participated_VBD in_IN the_DT all_DT aspects_NNS of_IN the_DT study_NN ,_,
        AL_NNP performed_VBD the_DT real_JJ time_NN PCRs_NNP ,_, MH_NNP critically_RB evaluated_VBD
        the_DT results_NNS and_CC DvB_NNP is_VBZ the_DT principal_JJ investigator_NN ._.
      
    
  
